|Bid||0.00 x 800|
|Ask||0.00 x 1000|
|Day's Range||17.10 - 18.11|
|52 Week Range||11.85 - 53.70|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||38.33|
Geoff MacKay, AVROBIO’s President and Chief Executive Officer, will provide an overview of the Company and a business update. A live webcast of the presentation will also be available under "Events and Presentations" in the Investors section of the Company's website at www.avrobio.com.
AVROBIO, Inc. (AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced clinical trial updates from the ongoing investigator-sponsored Phase 1 clinical study and the AVROBIO-sponsored Phase 2 clinical trial of AVR-RD-01. AVR-RD-01 is an investigational gene therapy candidate designed to treat Fabry disease by inserting the GLA gene that encodes functional α-galactosidase A (AGA, the enzyme that is deficient in patients with Fabry disease) with the goal of enabling continuous endogenous AGA production and distribution to tissues and organs.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Does the February share price for AVROBIO, Read More...
CAMBRIDGE, Mass., Feb. 01, 2019 -- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced a time change for its analyst.
The Phase 1/2 clinical trial is a planned investigator-sponsored trial to be conducted by the University of California, San Diego (UCSD) under the direction of Stephanie Cherqui, PhD, Associate Professor in the Department of Pediatrics at UCSD and a leading expert in stem cells and gene therapy for cystinosis.
CAMBRIDGE, Mass., Jan. 17, 2019 -- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced that clinical trial updates.
Dr. Vickers brings a wealth of global pharmaceutical and biotechnology expertise to AVROBIO, with more than 25 years’ experience in the development and approval of innovative biologics and small molecules to treat diseases in a wide range of therapeutic areas. The Company also announced that Scott Requadt is transitioning off AVROBIO’s board to become CEO of a Blackstone portfolio company. “Phil is a great addition to our Board,” said Geoff MacKay, President and CEO of AVROBIO.
AVROBIO, Inc. (AVRO), (“The Company”) a Phase 2 clinical-stage gene therapy company, today announced that the Company has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ:NBI). The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology and ranked on an annual basis.
Is AVROBIO, Inc. (NASDAQ:AVRO) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before doing days of research on it. Given their 2 and 20 payment structure, hedge funds have more resources than the average investor. The funds have access to […]
Three of them, Birgitte Volck, M.D., Ph.D., President of Research and Development, Erik Ostrowski, Chief Financial Officer, and Steven Avruch, General Counsel, will report to AVROBIO’s President and CEO, Geoff MacKay. The fourth, Josie Yang, Ph.D., Vice President and Head of Regulatory Affairs, will report to Dr. Volck.
With more and more genetic medicine companies going commercial, Leerink turned its attention to the sector this week. The Analyst Leerink’s Mani Foroohar initiated coverage of 10 genetic medicine companies ...
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
“The third quarter has been productive for AVROBIO,” commented Geoff MacKay, President and Chief Executive Officer of AVROBIO. “In a recent clinical data update on AVR-RD-01, we were pleased with the α‑galactosidase A (AGA) enzyme activity demonstrated in patients with Fabry disease. In addition, we have achieved our first regulatory milestone for our gene therapy for Gaucher disease as it advances towards the clinic.
Avrobio Inc (NASDAQ: AVRO ), a developer of gene therapy drugs targeting rare lysosomal storage disorders such as Fabry disease, Gaucher disease, Pompe disease and cystinosis, recently offered 5.25 million ...